103 related articles for article (PubMed ID: 9315836)
1. Community-acquired pneumonia: need for a cost-effective approach to treatment.
Prabhudesai PP; Kuruvilla T; Tadvi S
Chest; 1997 Sep; 112(3):861-2. PubMed ID: 9315836
[No Abstract] [Full Text] [Related]
2. Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy.
Breuer O; Blich O; Cohen-Cymberknoh M; Averbuch D; Kharasch S; Shoseyov D; Kerem E
Pediatr Pulmonol; 2015 May; 50(5):495-502. PubMed ID: 25652187
[TBL] [Abstract][Full Text] [Related]
3. Oral antibiotics for the treatment of severe pneumonia in children.
Klugman KP; Madhi SA
Lancet; 2004 Sep 25-Oct 1; 364(9440):1104-5. PubMed ID: 15451204
[No Abstract] [Full Text] [Related]
4. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
[TBL] [Abstract][Full Text] [Related]
5. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy.
Rhew DC; Hackner D; Henderson L; Ellrodt AG; Weingarten SR
Chest; 1998 Jan; 113(1):142-6. PubMed ID: 9440581
[TBL] [Abstract][Full Text] [Related]
6. Community-acquired pneumonia in Ugandan adults: short-term parenteral ampicillin therapy for bacterial pneumonia.
Yoshimine H; Oishi K; Mubiru F; Nalwoga H; Takahashi H; Amano H; Ombasi P; Watanabe K; Joloba M; Aisu T; Ahmed K; Shimada M; Mugerwa R; Nagatake T
Am J Trop Med Hyg; 2001; 64(3-4):172-7. PubMed ID: 11442214
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic treatment of children with community-acquired pneumonia: comparison of penicillin or ampicillin versus cefuroxime.
Dinur-Schejter Y; Cohen-Cymberknoh M; Tenenbaum A; Brooks R; Averbuch D; Kharasch S; Kerem E
Pediatr Pulmonol; 2013 Jan; 48(1):52-8. PubMed ID: 22431471
[TBL] [Abstract][Full Text] [Related]
8. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
Todisco T; Dal Farra F; Ciliberti G; Pirina P; Guelfi R; Serra G; Paris R; Mancuso I; Cepparulo M
J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study between ampicillin and hetacillin].
Mazzei CM; Lasala FG; Gherardi CR; Bellomo J
Prensa Med Argent; 1972 Jun; 59(19):728-33. PubMed ID: 5051454
[No Abstract] [Full Text] [Related]
10. [Clinical efficacy of probiotics in complex treatment of called-up servicemen with community-acquired pneumonia].
Rakov AL; Grinevich VB; Kriukov AE; Bogdanov IV; Rysev AV; Zakharchenko MM; Dobrenko VA; Gubonina IV
Voen Med Zh; 2006 Apr; 327(4):15-22. PubMed ID: 16784101
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Dresser LD; Niederman MS; Paladino JA
Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
[TBL] [Abstract][Full Text] [Related]
12. Community-acquired pneumonia: treatment at home or in the hospital?
Aujesky D; Fine MJ
Am J Med; 2008 Dec; 121(12):1038-40. PubMed ID: 19028194
[No Abstract] [Full Text] [Related]
13. [Pharmacoeconomic estimation of cost of community acquired pneumonia therapy].
Kulidzhanov AIu; Sirotko II; Koriakin PM; Korchazhkin VS
Voen Med Zh; 2001 Jan; 322(1):50-2. PubMed ID: 11219929
[No Abstract] [Full Text] [Related]
14. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Samsa GP; Matchar DB; Harnett J; Wilson J
Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
[TBL] [Abstract][Full Text] [Related]
15. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
Kohno S; Yanagihara K; Yamamoto Y; Tokimatsu I; Hiramatsu K; Higa F; Tateyama M; Fujita J; Kadota J
J Infect Chemother; 2013 Dec; 19(6):1035-41. PubMed ID: 23695232
[TBL] [Abstract][Full Text] [Related]
16. A clinical and economic study of community-acquired pneumonia between single versus combination therapy.
Hasali MA; Ibrahim MI; Sulaiman SA; Ahmad Z; Hasali JB
Pharm World Sci; 2005 Jun; 27(3):249-53. PubMed ID: 16096896
[TBL] [Abstract][Full Text] [Related]
17. Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.
Okimoto N; Kurihara T; Honda N; Asaoka N; Fujita K; Ohba H; Nakamura J
J Infect Chemother; 2003 Jun; 9(2):183-6. PubMed ID: 12825120
[TBL] [Abstract][Full Text] [Related]
18. Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis.
Lorgelly PK; Atkinson M; Lakhanpaul M; Smyth AR; Vyas H; Weston V; Stephenson T
Eur Respir J; 2010 Apr; 35(4):858-64. PubMed ID: 19717479
[TBL] [Abstract][Full Text] [Related]
19. [The clinical and economic aspects of treating community-acquired pneumonias].
Tiurin VP; Dmitriev IuK; Duganov VK; Bogdanov MB
Voen Med Zh; 2000 Apr; 321(4):28-31. PubMed ID: 10860468
[No Abstract] [Full Text] [Related]
20. What's in a day?
Milbrandt EB; Angus DC
Chest; 2005 Nov; 128(5):3091-3. PubMed ID: 16304247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
